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Abstract Pulmonary infection by Nocardia is an uncommon opportunistic infection in humans.Thirty-five patients
withpulmonarynocardiosiswere identifiedintwotertiaryreferralhospitals.Aretrospectivereviewofthepatient char-
acteristics, clinical and laboratory features includingantimicrobial susceptibility atdiagnosiswas carried out.Radiological
features derived from chest radiographs and CTscans were also documented. In our population, the predominant risk
factorswere immuno-compromised state, corticosteroid therapy, andunderlyingpulmonarypathology.The presenting
featureswere similar tothosepreviouslydescribedbutdisseminatedinfectionwasnotcommon.Theradiologicalchanges
were diverse andnon-specific.Nocardia asteroideswas the commonest species.Most Nocardia isolateswere susceptible
to imipenem, ceftriaxone, amikacin, andcotrimoxazole.Co-existingmicrobial agents are common andreflecttheunder-
lyingcomplexdisorders. r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1505, available online athttp://www.sciencedirect.com
Keywords pulmonary nocardiosis.INTRODUCTION
Nocardia species are Gram-positive, branching,
¢lamentous aerobic bacteria. Potentially pathogenic
strains ofNocardia to humans are found in soils and cause
cutaneous syndromes such asmycetomas or systemic in-
fections. Opportunistic systemic infections are uncom-
mon but well recognised especially in immuno-
compromised hosts including acquired immune de¢-
ciency syndrome (AIDS) patients. Pulmonary nocardiosis
is perhaps the most signi¢cant and may also spread by
the haematogenous route to a wide range of organs in-
cluding the brain.
We have retrospectively reviewed 35 patients with
pulmonary nocardiosis diagnosed in two tertiary refer-
ral hospitals in the last 5 years.We report here on the
clinical, microbiological and radiological features at diag-
nosis.To our knowledge, this represents the largest ser-
ies of patients with pulmonary nocardiosis in the
literature.Received 02 May 2002; Accepted in revised from 04November 2002
Correspondence should be addressed to Dr.Chi-hung Hui
Haematology, IMVS, FromeRoad, Adelaide, SA 5000, Australia.Fax: 61-
8-8222 5963. E-mail: chi-hung.hui@imvs.sa.gov.auMETHODS
A searchwas conducted via themicrobiology laboratory
databases of two tertiary referral hospitals that serve a
state population of around 1.5 million people. Patients
with at least one positive sputum or respiratory speci-
men (from bronchoscopic lavage or washings, endotra-
cheal tube aspirates or lung biopsies) for Nocardia
species were identi¢ed in the 5-year period from De-
cember1995 to December 2000. A retrospective review
of their case notes, laboratory results including micro-
biological investigations was carried out. The corre-
sponding radiological investigations were reviewed by
two radiologists (VA, JS).
Microbiological identi¢cation of Nocardiae
Allrespiratory specimenswere examinedbyGram stain.
Where microscopy indicated the presence of branching,
beaded, ¢lamentous Gram-positive bacilli, or colonies
suggestive of Nocardia grew on the standard plates ex-
tended cultures were performed. In addition to routine
culture, blood agar, blood agarwith nalidixic acid-colistin
and Lowenstein-Jensen + glycerol and charcoal yeast
agar were set up and incubated for a minimum of 7 days
710 RESPIRATORYMEDICINEat 351C in a CO2 -enhanced environment.Genus identi¢-
cation of Nocardia was based upon appearance under
Gram stain, staining with the modi¢ed Ziehl^Neelsen
technique and colony morphology (a white creamy yel-
low colony with powdery surface). Species identi¢cation
wasusuallyperformedby sequencingof the16Sribosomal
RNAgene andcomparisonof the sequence obtainedwith
the genetic database Genbanks (National Center of Bio-
technology Information,NIH, Bethesda, Maryland,USA).
Sequence homology of greater than 99% was considered
as de¢nite identi¢cation. Sensitivity testing to a panel of
antibiotics was performed by the Kirby-Bauer disc di¡u-
sionmethod as described forNocardia isolates (1).
De¢nitions
Co-existence of other microbial pathogens was de¢ned
by a positive culture from either the same respiratory
specimen or another specimen within 7 days of detec-
tion of pulmonary nocardiosis.The signi¢cance of identi-
¢cation ofNocardiawas arbitrarily de¢ned as the clinical
decision to institute anti-Nocardia therapy or as assessed
bymicrobiologists at the time of management.
RESULTS
Patient characteristics
Thirty-¢ve patients with Nocardia recovered from re-
spiratory specimenswere identi¢ed in the 5-year period,
which represents an annual incidence of at least 4.7 per
million. Patients comprised 21men and 14 women (male
to female ratio1.5:1) with amedian age of 65 years (range
25^90) at diagnosis.
Table1shows the underlying diseases and relevant treat-
ment histories of these patients.The majority (22/35 or
63%) of themhad anunderlyingrespiratorydisorder ran-
ging from common conditions such as chronic obstruc-
tive airway disease (COAD), asthma and bronchiectasis
to less common ones such as previous tuberculosis and
cystic ¢brosis. Multiple co-existing respiratory pathol-
ogy was not unusual. The non-respiratory disorders
comprised patients with underlying haemopoietic or
non-haematologicalmalignancies, solid organ ormarrow
transplantation, autoimmune disorders, and non-malig-
nant CD4 lymphopenia including one HIV positive pa-
tient. Among all patients, 21 (60%) were receiving
corticosteroids and/or other forms of immuno-suppres-
sive therapy. Therefore, in this population, almost all of
our patients (33/35 or 94%) with pulmonary nocardiosis
had an underlying respiratory pathology and/or were
’immuno-compromised’ as a result of their underlying
diseases or treatment.Nevertheless, there were excep-
tions, with two previously healthy patients (cases 34 and
35) being noted. Furthermore, there did not seem tohave an obvious relationship with smoking history
(29%), diabetesmellitus (28%) or particular occupations.
Clinical and laboratory features
Table 2 summarises the presenting clinical features and
laboratory investigations of the patients. Respiratory
symptoms (cough and shortness of breath) were fre-
quently present.There was no consistent description of
the sputum colour when this was a prominent symptom.
Fever and systemic symptoms were also common.
Pleuritic chest pain was noted in nearly one-third of pa-
tients.The caserecords didnot allow an accurate apprai-
sal of the interval between the onset of symptoms and
the diagnosis but a delay of 5 months was documented
in one of the cases.
A mild leucocytosis with neutrophilia (mean neutro-
phil count10.6109/l, range 3.3^23.5109/l) and an ele-
vated C-reactive protein (mean level 108mg/l, range 11^
230mg/l) were noted.Data on changes in arterial blood
gases or lung function studies prior to diagnosis were in-
su⁄cient to allowmeaningful analysis.
Sputum samples were able to provide themicrobiolo-
gical diagnosis in nearly half of the patients, whilst
bronchoscopic procedures allowed the diagnosis to be
made in an additional two-¢fths. However, a targeted
procedure such as CT-guided ¢ne needle aspiration or
lung biopsy was required in ¢ve patients.
Lung biopsieswere available in four patients, revealing
typical acute necrotising pneumonia with abscess (Fig.1)
or non-speci¢c in£ammationwith ¢brosis.Histopatholo-
gically, only one of the four specimens allowed ready
identi¢cation of the organism with methenamine silver
stains.
Disseminated systemic nocardiosis beyond the lungs
was actively sought (by at least a CTor MRI of the brain)
in11patients.Threepatients (8.5% overall) had haemato-
genous spread of nocardiosis: the scapula in one, the
brain and nocardial bacteraemia in another, andmultiple
sites in the other patient.
Radiological features
Radiological examinations at diagnosis were available for
review in 23 patients and results are shown inTable 3.
All 22 patientswith chest radiographs available for re-
view were abnormal. The commonest abnormality was
non-segmental air-space consolidation (68%) andnot un-
commonly involvingmultiple areas. Pulmonary nodule(s)
was the next most common manifestation found in
55%Fsolitary pulmonary nodules (SPN) being slightly
more frequent than multiple nodules. Cavitation was
seen in one of seven patients with SPNs and two (includ-
ing case 26) of the ¢ve patients with multiple nodules.
TABLE 1. Underlyingdiseases andrelevanttreatmenthistories of patientswith pulmonarynocardiosis.
Case Sex/age Underlyingdiseases Relevanttreatmenthistory
1 F71 COAD Prednisolone 5mgdaily for years
2 M90 COAD F
3 F77 COAD/asthma, bronchiectasis Prednisolone15mgdaily, home oxygen
4 M68 COAD/asthma; bronchopulmonary aspergillosis Prednisolone ceased 2 monthsprior
5 M53 COAD/asthma; bronchopulmonary aspergillosis Prednisolone 25mgdaily fornon-
respiratory indication
6 M71 COAD; primarypulmonary ¢brosis Prednisolone 50mgdaily; home oxygen
7 F72 COAD; bronchiectasis; cyclicalneutropenia Prednisolone 7.5 mgdaily; granulocyte-
colony-stimulating factor 3 every 2 weeks
8 M81 COAD; interstitial lungdiseasewith ¢brosis;
adenocarcinoma ofthe lung
Radiotherapy to lung; home oxygen,
prednisolone
9 M64 COAD; metastatic adenocarcinoma of
colonto lungandbones
Dexamethasone for palliation
10 M54 Asthma; allergic bronchopulmonary aspergillosis Prednisolone 5mgdaily for years
11 F71 Asthma; bronchiectasis; previous
Mycobacterium avium-intracellulare infection
Prednisolone12.5mgdaily
12 F48 Asthma; bronchiectasis F
13 M75 Asthma; obstructive sleep apnea Home oxygen
14 F77 Late onset bronchiectasis F
15 M41 Cystic ¢brosiswith bronchiectasis, sinusitis Prophylactic antibiotic
16 F86 Previouspulmonary tuberculosiswith lobectomy
and thoracoplasty
F
17 M57 Wegener’sgranulomatosis; asthma; bronchiectasis Prednisolone 50mg + cyclophosphamide
100mgdaily
18 M74 Poorlydi¡erentiated small cell lungcancer with
scalp and lung secondaries
F
19 M72 Bronchiectasis;Waldenstrom’smacroglobulinemia Chlorambucil and Prednisolone for years
then cyclophosphamide
20 M72 Asthma;Kyphoscoliosis; chronic lymphatic leukemia for years F
21 M58 Relapsed advancednon-Hodgkin’s lymphoma Prednisolone + vincristine; abdominal
radiotherapy;Previous combination
chemotherapy
22 M58 Hodgkin’s disease, previous autologousmarrow transplant,
complicated byprobable autologoushepatic
graft vs. hostdisease
Prednisolone100mgdaily +
cyclosporin A150mg Bd
23 M62 Angioimmunoblastic lymphadenopathy
withtransformation
to lymphoma;COAD
Prednisolone formonths then combination
CHOPchemotherapy
24 F30 Acutemyeloid leukaemia post second allogeneicmarrow
transplantwith grade IV graft vs. hostdisease
Antithymocyte globulin, methylprednisolone,
mycophenolate, antiinterleukin-
2 receptor (anti-T-lymphocyte) antibodies,
and Intravenous immunoglobulins
25 F48 Possible idiopathic CD4 lymphopenia,
blood CD4 count:130/ml
F
26 M40 HIVinfection diagnosed at same admission, blood
CD4 count: 32/ml; alcoholic;Hepatitis C
F
27 F84 Disseminated ovarian cancerdiagnosed at same admission F
28 M34 Glioblastomamultiforme ofthe brain Post-operative cranialradiotherapy,
chemotherapy; dexamethasone 8mgdaily
29 F62 Renal transplant for IgAnephropathy Prednisolone15mg + cyclosporin A +
mycophenolate
30 F25 Renal transplantthen combinedrenal and
pancreatic transplant 2 years later.Complicated by
(i) post-transplant lympho-proliferative
disease of pancreas andkidney;
(ii) renalvein thrombosis on
haemodialysis
F
PULMONARYNOCARDIOSIS 711
31 M39 Heart-lung transplant1994 for severe
steroid-dependent asthma and
bronchiectasis and dilated cardiomyopathy.
Complicated by MAI, aspergillosis,
CMV colitis, pseudomonas, bronchiolitis obliterans
Prednislone10mgdaily +
tacrolimus 4mg Bd + azathioprine
150mgdaily;Previous Anti-thymocyte
globulin andmethylprednisolone
32 M65 Microscopic polyarteritis nodosawith chronic renal failure Prednisolone 80mg + cyclophosphamide
50mgdaily
33 M40 Nil (Refractoryclusterheadache) Prednisolone 75mgdaily
34 F77 Nil (spinal stenosis) F
35 F74 Nil F
Abbreviations:COAD = chronic obstructive airwaydisease;MAI =mycobacterium
avium-intracellulare;CMV = cytomegalovirus;CHOP = cyclophosphamide, doxorubicin, vincristine, prednisolone
TABLE 1. Continued
Case Sex/age Underlyingdiseases Relevanttreatmenthistory
TABLE 2. Presenting symptoms andlaboratory features
of patientswith pulmonarynocardiosis.*
Cough 57%
Shortness of breath 50%
Fever 36%
Sputum 32%
Chest pain 29%
Anorexia and loss of weight 21%
Haemoptysis 7%
Confusion 7%
Disseminated infection 8.5%
Scapularmass (1)
Brain andnocardial bacteraemia (1)
Retina, skin, andpara-spinalmass (1)
Meanwhite cell count atdiagnosis 12.7109/l
Mean absolute neutrophil count 10.6109/l
Mean C-reactive protein 108mg/l
Theyield of various diagnostic specimens
sputum 47% (16)
BAL 44% (15)
Endotracheal tube aspirate (1)
CT chest-guided ¢neneedle aspiration } 14% (4)
Video-assisted thoracoscopic lung biopsy} (1)
*Number inparentheses.
712 RESPIRATORYMEDICINEPleural e¡usion and lobar consolidation were uncom-
monly observed (18%).
On 11 CT scans of the chest, pulmonary nodules,
either solitary ormultiple, were seen in 64%, with three
of seven showing cavitation.These noduleswere ofmod-
erate size ranging from 1 to 3 cm. An irregular mass of
more than 3 cm was seen in one case. Non-segmental
air-space consolidationwas seen in 55%, with lesions fre-
quently abutting the pleural surfaces, and occasionally
extending to the chest wall. A mixed pattern of consoli-dation and pulmonary nodules was often apparent.
Pleural e¡usion was detected in 36%. Lobar consolida-
tion or ground-glass opacities were uncommon. Never-
theless, ground-glass opacity was the only abnormality
noted in one patient.
Therewas no zonal preference of involvement shown by
either chest radiographyor CT.The spectrum of radiolo-
gicalmanifestations is illustrated in Fig. 2.
Microbiological features
Table 4 shows the species identi¢cation of the Nocardia
isolates among these patients. N. asteroides accounts for
60% of all the nocardiae successfully identi¢ed. This was
followed by N. nova, N. farcinica and N. transvalensis while
the other species such asN. brasiliensiswere less common.
Table 5 shows the antimicrobial sensitivity patterns
that were available in 22 isolates. Susceptibility in vitro to
cotrimoxazole was found in 80%, compared to 90% sus-
ceptibility to imipenem. Ceftriaxone and amikacin ap-
peared to have signi¢cant in vitro activity against
Nocardia, although the number studied was limited.On
the contrary, other aminoglycosides, the tetracycline
group, erythromycin, quinolone (cipro£oxacin), and am-
picillin had in vitro activity against less than 50% of the
isolates tested. Antimicrobial sensitivity of Nocardia spp
may assist with species identi¢cation as characteristic
patterns may occur. For example, N. nova is the only
group sensitive to erythromycin and N. farcinica is cefo-
taxime resistant.
Recovery of additional organisms simultaneously or
temporally close to the positive specimens for Nocardia
was very common in our patient group (21/35 or 60%).
Multiple microbial agents (more than two) were present
in eight cases. Table 6 shows the frequency of the
FIG. 1. Pulmonarynocardiosis.AnH& E section fromvideo-assisted thoracoscopic lungbiopsy frompatient17, showingnecrotising
pneumonia with abscess formation and extensive in¢ltration by neutrophils (left  40).The branching, beaded organisms were de-
monstrableinthe Ziehl^Neelsen stain (topright 100) andGrocott’smethenamine silver stain (bottomright 100). (Courtesyof Dr.
A.Mahar, pulmonaryhistopathologist,Royal Adelaide Hospital).
TABLE 3. Radiological ¢ndings of patientswith pulmonarynocardiosis*
Chest radiographs (available for reviewin 22 patients)
Non-segmental consolidation: 68% (15)
Pulmonarynodule(s) 55% (12)
Solitarypulmonarynodule 32% (7, with one showingcavitation)
Multiple nodules 23% (5, withtwo showingcavitation)
Lobarconsolidation: 18% (4)
Pleural e¡usion 18% (4)
CT chest (available for reviewin11patients)
Pulmonarynodule(s) 64% (7)
Solitarypulmonarynodule 36% (4, with one showingcavitation)
Multiple nodules 27% (3, withtwo showingcavitation)
Non-segmental consolidation 55% (6)
Pleural e¡usion 36% (4)
Lobarconsolidation 9% (1)
Ground-glass opacities 9% (1)
Zonalprevalence
Mid 31% (5)
Mid/lower 25% (4)
Upper 25% (4)
Lower 19% (3)
*Actualnumber inparentheses.
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FIG. 2. The diverse radiologicalmanifestations of pulmonarynocardiosis. (a) Chest radiograph: non-segmental air-space consolida-
tionrightupper and lower lung zones. (b) Chest radiograph: mass-like consolidation attherighthilum, withmultiple nodules andnon-
segmental consolidation in the right lower lung zone. (c) CT chest: consolidation abutting the pleura. (d) Chest radiograph: SPN; the
backgroundofmultiple calci¢ednoduleswasduetounrelatedhealedgranulomatousdisease. (e) CT chest: multiple cavitatingpulmon-
ary nodules with consolidation (case 26). (f) CT chest: ground-glass opacity (case 23) is an unusualmanifestation of nocardiosis.The
abnormalities resolvedwith anti-Nocardia treatment.Background centri-lobular emphysematous changewas also noted.
714 RESPIRATORYMEDICINEco-pathogens detected, among which fungal species (no-
tably Aspergillus) occurred at the highest frequency.
Clinical progress and outcome
Twenty-six patients hadreceived anti-Nocardia treatment.
Threepatientswere notgiven speci¢c treatmentbecauseof their palliative status.The detection of nocardiosis was
considered to have little clinical signi¢cance in two pa-
tients (cases 7 and 16) who subsequently showed no evi-
dence of progressive nocardiosis at follow up. Treatment
history was not available in the remaining four patients.
Co-trimoxazolewas themostpopular induction ther-
apy and was given to 21patients, often over a prolonged
TABLE 6. Frequency of detection of possible pathogens
co-existingwith pulmonarynocardiosis.
Aspergillus species 10
PULMONARYNOCARDIOSIS 715period. Alternative therapy, usually imipenem or a com-
bination of cephalosporin and aminoglycoside, was given
to patients with allergy or resistance to co-trimoxazole
as suggested by sensitivity studies.
Outcome datawas incomplete as a portion of patients
were discharged to outpatient care by referring physi-
cians. Broadly speaking, follow-up information in 25 pa-
tients had recorded improvement in 14 (56%). Five
patients succumbed within the same admission. Six
others survivedmore than 2 months from the diagnosis
of pulmonary nocardiosis but died due to their underly-
ingmalignancies (in ¢ve) or severe COAD (in one).
DISCUSSION
Wehaveprovided a descriptive reviewof a large series of
patients with pulmonary nocardiosis and their clinical,
microbiological and radiological features at diagnosis.
The sporadic occurrence of this pulmonary disease in
man is related to inhalation of the sporulated, fragmen-
ted nocardial mycelia (2). The bacteria are ubiquitous in
the environment in soil, vegetablematter, and are foundTABLE 4. Species identi¢cation ofthe nocardial isolates.
N. asteroides 15
N. nova 3
N. farcinica 2
N. transvalensis 2
N. otitidiscaviarum (N.Caviae) 1
N. £avonozea 1
Mixed N. asteroides + N. brasiliensis 1
Unspeci¢ed 10
TABLE 5. Antimicrobial sensitivitypattern ofthe nocardial isolat
Antibiotics tested % sensitiv
Ceftriaxone 100
Imipenem 90
Amikacin 86
Cotrimoxazole 80
Augmentin 55
Cefotaxime 50
Tobramycin 40
Cipro£oxacin 27
Minocycline/doxycycline/tetracycline 23
Gentamycin 20
Erythromycin 20
Ampicillin 17
*Numbers in parentheses are expressed as sensitive strains ou
antibiotic.Intermediate susceptibilityresultswere omitted for simworldwide.Knownpathogenic species to humans include
N. asteroides, N. brasiliensis, N. otitidiscaviarum (N. caviae),
N. farcinica,N. nova,N. tranvalensis andN.pseudobrasiliensis
(3).N. asteroides is by far the commonest pathogen in the
nocardial genus and in pulmonary infection of our pa-
tients.
In our patient group, the major risk factors for pul-
monary nocardiosis were prolonged or high dose corti-
costeroid treatment, an immuno-suppressed state and
underlyingrespiratorypathology, often co-existing inpa-
tientswith complexmedicalproblems.Cellular immunity
mediated byT-lymphocytes is generally required follow-
ing phagocytosis for the de¢nitive control and elimina-
tion of Nocardia (4). Corticosteroids, the backbone of
immuno-modulatory or -suppressive therapy, impair the
lymphokine response to and phagocytic killing ofes*.
e isolates Susceptible to
resistant isolates
(5/5) F
(9/10) 9:1
(6/7) 6:1
(16/20) 4:1
(6/11) 6:5
(2/4) 1:1
(4/10) 2:3
(3/11) 3:7
(3/13) 3:10
(1/5) 1:4
(2/10) 1:4
(1/6) 1:5
t of a denominator of the number of isolates testedwith that
plicity.
Candida species 3
Other fungi (pencillium, alternaria,
paecilomyces species)
4
Pseudomonas species 4
Non-pseudomonasbacteria 5
Other bacteria
Mycobacteria (M. tuberculosis, M. fortuitum) 2
Legionella longbeachae (by serology) 1
In£uenza B 1
Others
Cytomegalovirus antigenaemia 1
Staphylococcus aureusbacteraemia 1
716 RESPIRATORYMEDICINEmicrobial agents by monocyte-macrophages (5). Not sur-
prisingly therefore, therecentlyreportedcases ofpulmon-
ary nocardiosis have been described in AIDS patients with
lymphopenia (6^8) or heavily immuno-suppressed indivi-
duals (9^19).Our patientswere similarly immuno-compro-
mised as a result of either an underlying haemo-
lymphopoieticmalignancy or corticosteroid treatment for
autoimmune disorders, organ transplants, and other neo-
plasms.Therelative rarityof AIDS in our patients probably
re£ects the low prevalence of HIV infection in the popula-
tion examined (700/1.5 million) (20), as well as a possible
bene¢t from co-trimoxazole prophylaxis prescribed to
thosewith lowCD4 counts.Nevertheless, the occurrence
of nocardiosis in a rare patient with idiopathic CD4 lym-
phopenia (case 25) is illustrative of the role of T-lympho-
cytes. Pulmonary nocardiosis in immuno-competent
patients with COAD is also increasingly recognized (6,
21^23).Abroadrange ofpulmonarypathology encompass-
ing anatomical, infective, neoplastic, vasculitic, and func-
tional defects was encountered in our patients.
As illustrated by our patients, the risk factors for pul-
monary nocardiosis that encourage the invasion by no-
cardia are synergistic.While nearly all our patients were
either immuno-compromised or hadunderlying pulmon-
ary pathology, it should be noted that two symptomatic
patients were previously well (24). Conversely, there
were patients in whom the identi¢cation of Nocardia
was regarded as insigni¢cant colonisation.This highlights
the di⁄culty sometimes of deciphering Nocardia in re-
spiratory specimens as ’opportunistic’ invaders or inno-
cent colonisers, when Nocardia is rarely a laboratory
contaminant.
We found, as have others (25), that the presenting
symptoms are usually referable to the respiratory tract
with associated constitutional disturbance. Cough is
usually productive with no speci¢c sputum colour.
Pleuritic chest pain usually re£ects pleural invasion from
a contiguous pneumonic infection. On the other hand,
disseminated extra-pulmonary infection was not com-
mon, occurring in less than10%.Compared to the higher
rate of 10^50% that has been previously reported
(6,15,25), our lower incidence of metastatic infection
may re£ect earlier diagnosis or di¡erent immunological
defects in di¡erent settings. A signi¢cantly raised C-re-
active protein is considered a laboratory hallmark of sys-
temic infection and should prompt a search for infective
etiology.Neutrophilia was not reliably present.
The diverse radiological manifestations of pulmonary
nocardiosis re£ect their ability to cause both suppura-
tive andgranulomatous infection (26,27).Onchest radio-
graphs, non-segmental consolidation and pulmonary
nodule(s) are the commonermanifestations,while pleur-
al e¡usions are uncommon. Cavitatory nodules or mass
lesions have beenmore commonly described in AIDS pa-
tients (28,29) but were not a prominent feature in this
series, probably re£ecting the lower proportion ofAIDSin this study. It is noted however, that our only HIV posi-
tive patient also showed a cavitatory lesion (see Fig. 2).
On CT chest studies, solitary ormultiple pulmonary no-
dules thatreach 3 cmin size andconsolidationwere com-
monly seen. Although there is no distinctive CT feature
for pulmonary nocardiosis, CTo¡ers better delineation
of the location and extent of disease involvement
(16,30), andmayguidebiopsy if required.Ouroverall ¢nd-
ings con¢rm previous reports (8,16,28). Neither the
chest roentgenograms nor CT chest appearances were
pathognomonic or speci¢c.
We found that sputum studies permitted the diagnosis
in half of the patients and should never be omitted.On
the other hand, half of the patients required additional
alternative specimens and bronchoscopic lavage (BAL)
undoubtedly provides a better yield when performed. A
low threshold of performing BAL for immuno-compro-
mised patients with pneumonia when initial investiga-
tions are negative or when there is a lack of response to
conventional antibacterials requires emphasis. Lung
biopsy specimens in this context should always be sent
for microbiological studies. Histopathological sections
with routine haematoxylin and eosin stain cannot visua-
lise the ¢lamentous bacteria while methenamine-silver
preparationsmay not always identify them. In themicro-
biology laboratory, the diagnosis ofNocardia is suggested
when the gram-stained smears show tangled masses of
branching bacilli with characteristic ‘beaded’ staining.
One must be aware that Nocardia may fragment into
coccoid forms and can be partially acid-fast. Therefore,
not every acid-fast bacillus is a mycobacteria (31).
Therapeutically, co-trimoxazole is the most popular
initial treatment. Susceptibility testing of Nocardia iso-
lates and precise species identi¢cation facilitate the
choice of alternative regimens when patients are allergic
to sulphur compounds or when the organisms are resis-
tant. In our locality, parenteral imipenem, ceftriaxone,
and amikacin appear to beuseful alternatives.Thepoten-
tial of these agents has also been reported previously
(18,19,21,22,32), with recent advocate of imipenem^ami-
kacin combination as initial therapy (22). Prolonged
treatment of 6^12 months duration is usually recom-
mended to prevent dissemination and recurrence yet
the optimal duration for immuno-compromised patients
remains uncertain.
Another ¢nding that has not been emphasised pre-
viously (11,19) is the high incidence of co-existing micro-
bial agents, such as Aspergillus spp. This phenomenon
likely re£ects the immunode¢ciency state or predispos-
ing pathology of the respiratory tract. Whether these
are colonisers or co-infective agents may not always be
obvious. A mixed growth, however, will limit the diag-
nostic certainty regarding which organism is contribu-
tory to patient symptoms.
Likewise, the signi¢cance of Nocardia spp. recovered
from smears or cultures of respiratory specimens is not
PULMONARYNOCARDIOSIS 717always clear-cut as discussed earlier. Most of our epi-
sodes were considered as signi¢cant based on the arbi-
trary designation when anti-Nocardia therapy had been
given. Traditionally, most clinicians would not disregard
their isolation in association with abnormal pulmonary
radiology, immuno-suppressed patients, concomitant
neurological symptoms and signs, skin abscess without
obvious pathogen (33), or repeatedpositivity frommulti-
ple cultures (3,34). Until we have better tools to deter-
mine the virulence of Nocardia spp., clinicians have to
make an imprecise judgement whether to treat cases
without obvious high-risk features. This relies on an un-
derstanding of the underlying medical disorder, knowl-
edge of previous microbiological results, liaison with a
microbiologist, and ultimately, assessment of the overall
clinical picture at the bedside.
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